Is Lorlatinib effective against bone metastasis?

Non-small cell lung cancer is the most common cancer. As the tumor grows, it blocks or narrows the airways, making breathing difficult. Eventually, the tumor cells will spread to nearby lymph nodes or to the liver, bones, adrenal glands, brain, etc. Lorlatinib is used to treat patients with non-small cell lung cancer with ALK mutations. It is a third-generation targeted drug and has certain effects on patients with bone metastases. Relevant studies have shown that the ORR is 48%, the complete response rate is 4%, the partial response rate is 44%, and the median duration of response is 12.5 months.

Some drugs can have undesirable or dangerous effects when used with

If a patient vomits shortly after taking lorlatinib, do not take another dose until the next scheduled dose. If you want to get more high-quality information, you can contact YaoDe. YaoDe will do its best to learn more about high-quality overseas drugs for you.

xa0

xa0

xa0

xa0

xa0

xa0